. . . . . . . . . . . . . "a(SCHEM:Bevacizumab) -| p(HGNC:VEGFA)" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "bevacizumab, a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical trial development and has shown promising results in clinical trials" . . "Selventa" . . . . "2014-07-03T14:30:23.893+02:00"^^ . . .